Compare DLHC & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | ASRT |
|---|---|---|
| Founded | 1969 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 75.1M |
| IPO Year | N/A | 1997 |
| Metric | DLHC | ASRT |
|---|---|---|
| Price | $5.90 | $11.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 11.9K | ★ 78.4K |
| Earning Date | 02-05-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $344,497,000.00 | $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | $62.56 | ★ N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $2.72 | $7.71 |
| 52 Week High | $8.25 | $15.15 |
| Indicator | DLHC | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 85.44 |
| Support Level | $5.51 | $9.11 |
| Resistance Level | $6.23 | $12.29 |
| Average True Range (ATR) | 0.22 | 0.63 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 42.05 | 78.30 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.